Drug Response Profiling at KIYATEC

Complex Co-Culture Model Development

Learn about the world’s most advanced ex vivo immuno-oncology models.

Drug Response Profiling Services

3D cell culture service offerings & in vitro model development

Predicting Clinical Response

Learn more about our clinically relevant, predictive 3D response assays

KIYATEC Brochures & Posters

Recent News

KIYATEC Announces Inaugural SAB Members

Tags : 

KIYATEC Announces Inaugural Scientific Advisory Board Members Experts to Provide Invaluable Insight and Guidance to Advance Predictive Cancer Diagnostics. Members:  Carlos L. Arteaga, MD (Vanderbilt University), David Kaplan, PhD (Tufts University), Anil Sood, MD (MD Anderson) Greenville, S.C. | April 4, 2016 – KIYATEC, a leader in emerging 3D ex vivo predictive cancer diagnostics, today announced the

Read More

3 KIYATEC Posters @AACR 2016

Tags : 

Three KIYATEC abstracts accepted for poster presentations during 2016 AACR Conference in New Orleans KIYATEC, a private company prioritizing accurate ex vivo prediction of patients’ response to drug treatment, received acceptance of three posters for presentations during the upcoming AACR conference. GREENVILLE, SC, March 21, 2016– KIYATEC Inc. is pleased to announce that three abstracts

Read More

NCI Contract: Cancer Stem Cell / Lung Cancer Project

Tags : 

National Cancer Institute (NCI) Awards KIYATEC $1.725M to Develop Cancer Stem Cell (CSC) Expansion Technology  Contract Funds 3D Cell Culture Technology Platform to Expand CSCs for Small Cell Lung Cancer (SCLC) Model Development GREENVILLE, SC | October 22, 2015 – KIYATEC announced today the award of a Fast Track Phase I and Phase II Small Business Innovation Research (SBIR)

Read More

NIBIB Contract: 3D Bone Marrow Mimetic

Tags : 

National Institute of Biomedical Imaging and Bioengineering (NIBIB) Awards KIYATEC $225,000 to Develop 3D Platelet Bank  Contract Funds 3D Microbioreactor Bone Marrow Mimetic for Platelet Production GREENVILLE, SC | September 30, 2015 – KIYATEC announced today that it has been awarded a $225,000 Small Business Innovation Research (SBIR) Phase I Grant from the National Institute of

Read More

KIYATEC Places 2nd @ RESI 2015 in Boston

KIYATEC PLACES 2ND AT REDEFINING EARLY STAGE INVESTMENTS (RESI) BOSTON The conference showcased 30 of the most innovative life science technology companies and winners were chosen by investors, researchers and executives vote in RESI cash. BOSTON, MA | September 16, 2015 – KIYATEC Inc. is pleased to announce that our RESI Conference poster entitled “The Business of Accurately Predicting Drug Response of

Read More

Learn More About KIYATEC

x Shield Logo
This Site Is Protected By
The Shield →